Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

V-10153 (Vernalis).

Farhad Kamali1

  • 1Wolfson Unit of Clinical Pharmacology, University of Newcastle-upon-Tyne, NE1 7RU, UK. Farhad.Kamali@newcastle.ac.uk

Current Opinion in Investigational Drugs (London, England : 2000)
|September 29, 2005
PubMed
Summary

Vernalis is developing V-10153, a novel stimulator of plasminogen activators, for treating thrombotic disorders and cardiovascular disease. Clinical trials in acute myocardial infarction were completed, with plans for stroke trials underway.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Translation of a physiologically-based pharmacokinetic model for dabigatran etexilate to the design of a safety and efficacy study in post-partum women.

British journal of clinical pharmacology·2025
Same author

The impact of <i>CYP2C9</i>, <i>VKORC1</i>, and <i>CYP4F2</i> polymorphisms on warfarin dose requirement in Saudi patients.

Frontiers in pharmacology·2025
Same author

A randomised crossover design study comparing the pharmacokinetics and pharmacodynamics of two single doses of oral aspirin (75 mg vs 150 mg) in pregnant women at risk of pre-eclampsia: a response to the letter to editor.

American journal of obstetrics and gynecology·2024
Same author

Comparing 75mg vs 150mg aspirin in pregnancy women at risk of preeclampsia.

American journal of obstetrics and gynecology·2024
Same author

A randomized crossover design study comparing the pharmacokinetics and pharmacodynamics of 2 single doses of oral aspirin (75 mg v 150 mg) in pregnant women at risk of preeclampsia: implications on assessing aspirin response and patient adherence to therapy.

American journal of obstetrics and gynecology·2024
Same author

Assessment of exposure to direct oral anticoagulants in elderly hospitalised patients.

British journal of haematology·2021

Area of Science:

  • Pharmacology
  • Cardiovascular Medicine
  • Biotechnology

Background:

  • Thrombotic disorders and cardiovascular disease represent significant global health challenges.
  • Current treatments for these conditions have limitations and unmet needs.
  • Recombinant plasminogen activator stimulators offer a potential new therapeutic approach.

Purpose of the Study:

  • To evaluate the development of V-10153, a recombinant plasminogen activator stimulator.
  • To assess the potential of V-10153 in treating thrombotic disorders and cardiovascular disease.
  • To report on the progress of clinical trials for V-10153.

Main Methods:

  • Phase II clinical trial design for acute myocardial infarction.
  • Planned Phase II clinical trial for stroke patients.
  • Development of a recombinant plasminogen activator stimulator (V-10153).

Main Results:

  • A Phase II trial in acute myocardial infarction was completed by March 2004.
  • Data from the completed Phase II trial are anticipated.
  • Preparations for a Phase II trial in stroke were in progress by July 2005.

Conclusions:

  • V-10153 shows promise as a novel therapeutic agent for cardiovascular conditions.
  • Further clinical evaluation in stroke is planned.
  • The development of V-10153 is progressing through clinical trials for thrombotic disorders.

Related Experiment Videos